CROs vs CMOs, and CDMOs: What’s the difference between the three?
Author:
Thermo Fisher Scientific Content Team
Category | CDMO Services
Key takeaways
- Contract research organizations (CROs) support biotech and pharma companies with clinical research and clinical trial services.
- Contract manufacturing organizations (CMOs) manufacture innovative drug substances and drug products and offer related expertise.
- Contract development and manufacturing organizations (CDMOs) provide end-to-end, integrated support across the drug lifecycle—they may also offer clinical trial services.
- Integrated models: For some programs, integrating CDMO and CRO capabilities (including clinical supply) can help reduce vendor handoffs and streamline operations.
Developing, manufacturing, and researching an investigational new drug (IND) is an intense undertaking with many moving parts. From discovery and development through preclinical studies and testing, clinical trials, review and approval, and market commercialization, biotechnology and pharmaceutical companies must navigate complex regulatory requirements and check off operational milestones—many of which may differ by region.
To bridge internal resource gaps, sponsors often partner with third-party providers—most commonly CROs, CMOs, or CDMOs. But what’s the difference between the three? This blog breaks down the difference between contract research organizations (CROs), contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs), and offers best practices for choosing the right model.
What’s the difference between CROs vs CMOs vs CDMOs?
Contract research organizations (CROs), contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs) all provide support on the drug development journey from molecule to medicine.
Although their solutions often overlap, their primary focus areas differ.
You need manufacturing capacity and scale-up support |
|||
| CDMO | Integrated development and manufacturing support | Formulation development, regulatory support, clinical materials, packaging, supply chain, QA, tech transfer | You want integrated development and manufacturing under one partnership |
| Integrated CDMO + CRO |
Coordinated development, manufacturing, and clinical research capabilities | Drug development, manufacturing, research, and clinical supply under connected governance | You want a more connected, end-to-end approach to reduce fragmentation |
What is a CRO (Contract Research Organization)?
A contract research organization, or CRO, supports biotechnology and pharmaceutical companies by providing a wide range of phase-appropriate research and development (R&D) offerings. Specifically, CROs help with clinical trial services including clinical research, regulatory affairs, clinical trial planning, site selection and initiation, recruitment support, clinical monitoring, data management, trial logistics, biostatistics, medical writing, and project management.
CROs can help coordinate and manage a clinical trial and its progress. Developing and manufacturing a new drug ultimately depends on a clinical trial’s progress from beginning to end. By outsourcing a comprehensive range of clinical trial services to a quality CRO, pharmaceutical, biotechnology, and medical device companies can leverage their knowledge, capabilities, infrastructure, and resources while simultaneously working on other important tasks.
What is a CMO (Contract Manufacturing Organization)?
A CMO helps sponsors manufacture their innovative drug substances and drug products. Their services can include commercial manufacturing, formulation development, analytical method development, stability testing, and production of registration batches. CMOs can help reduce costs and speed timelines by supplying the facilities, technology, and technical capabilities required to manufacture new therapies—whether small molecules or large molecules—without the need for significant upfront capital investment.
Additionally, CMOs help pharmaceutical and biotechnology companies stay compliant with quality standards and regulatory requirements, helping to avoid any roadblocks on the drug development and manufacturing journey—and allowing production to grow without compromising quality. By partnering with a CMO, pharmaceutical and biotechnology companies can effectively scale up their operations and limit financial risks while focusing on other tasks, including drug discovery and drug marketing.
What is a CDMO (Contract Development and Manufacturing Organization)?
A CDMO provides integrated drug development and manufacturing solutions and services under one roof. Specifically, CDMOs combine development expertise with manufacturing capabilities, reducing the need to work with multiple vendors and eliminating the risk that inherently comes with technology transfers. In recent years, certain CDMOs are also offering clinical research services—either through mergers and acquisitions or by expanding their in-house capabilities.
For sponsors seeking fewer handoffs and delays between the development and manufacturing stages, a CDMO model can provide seamless continuity and centralized oversight throughout the product lifecycle. Every year, the FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drugs for patients in need, and the race to market is more competitive than ever. That’s where CDMOs can step in—by serving as strategic partners for long-term success.
How to choose between a CRO, CMO, or CDMO?
There’s no “right” or “wrong” choice when it comes to picking a CRO vs a CMO vs a CDMO; it all comes down to your specific set of needs:
- Choose a CRO if you primarily need support with your clinical research and trial operations.
- Choose a CMO if your development process is defined and you need to scale manufacturing.
- Choose a CDMO if you want integrated development and manufacturing with fewer transitions.
That’s why it’s important to know the difference between the three— so you can confidently identify which entity is right for your program.
If you’re evaluating integrated CDMO and CRO support
If a fully end-to-end, integrated approach to drug development, manufacturing, and research sounds like a good fit for your needs, Thermo Fisher Scientific’s Accelerator™ Drug Development model may be right for your program—helping to reduce handoffs and minimize fragmentation.
By connecting CDMO and CRO capabilities across a coordinated suite of solutions, it allows sponsors to streamline their outsourcing approach across the entire drug development journey—from preclinical discovery to patient delivery—and ultimately get treatments to market faster.
From a sponsor standpoint, Accelerator™ Drug Development is centered on:
- Speed: One partner, eliminating timeline gaps and regulatory challenges while proactively mitigating risks.
- Flexibility: Innovative solutions across drug modalities and therapeutic areas, meeting your unique requirements.
- Partnership: A collaborative team with holistic oversight and integrated expertise across all phases, focused on your success.
Accelerator™ Drug Development is designed for programs where integration meaningfully reduces complexity. However, it does not replace CRO-only or CMO-only models when those approaches are strategically appropriate.
See how integrated CDMO and CRO solutions can help speed up your time to market
Summary
CROs, CMOs, and CDMOs each support the drug development journey in different ways—spanning clinical research (CRO), manufacturing (CMO), and integrated development and manufacturing (CDMO) services.
An integrated CDMO and CRO model, such as Accelerator™ Drug Development, may benefit programs seeking fewer handoffs and more connected execution across clinical research, manufacturing, and clinical supply.
Frequently asked questions (FAQs)
A CRO helps plan, manage, and execute clinical research and clinical trials. A CDMO provides integrated drug development and manufacturing services across the product lifecycle. In addition, some CDMOs often supply clinical trial materials (CTM).
Some CDMOs offer expanded capabilities, including clinical research services, either through in-house expansion or strategic acquisitions. This can create a more integrated service model, streamlining the transition from early-stage development through commercial production.
Accelerator™ Drug Development is a coordinated suite of solutions integrating CDMO and CRO capabilities across clinical research, manufacturing, and clinical supply. It is designed to support speed, flexibility, and partnership by reducing fragmentation between service providers and strengthening continuity from early development through commercialization.
An integrated approach can help reduce fragmentation and minimize handoffs by connecting clinical research, manufacturing, and clinical supply within a single, coordinated partnership. By aligning these capabilities under one connected framework, sponsors benefit from improved execution speed, adaptability across modalities, and more cohesive oversight.
